Back to Journals » Psoriasis: Targets and Therapy » Volume 8
Psoriasis: Targets and Therapy
ISSN: 2230-326X
- View all (136)
- Volume 14, 2024 (3)
- Volume 13, 2023 (7)
- Volume 12, 2022 (22)
- Volume 11, 2021 (14)
- Volume 10, 2020 (8)
- Volume 9, 2019 (13)
- Volume 8, 2018 (12)
- Volume 7, 2017 (9)
- Volume 6, 2016 (15)
- Volume 5, 2015 (13)
- Volume 4, 2014 (5)
- Volume 3, 2013 (4)
- Volume 2, 2012 (10)
- Volume 1, 2011 (1)
Archive: Volume 8, 2018
Psoriasis and sexual dysfunction: links, risks, and management challenges
Duarte GV, Calmon H, Radel G, Oliveira MDEF
Psoriasis: Targets and Therapy 2018, 8:93-99
Published Date: 10 December 2018
Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
Machado Á, Torres T
Psoriasis: Targets and Therapy 2018, 8:83-92
Published Date: 13 November 2018
Secukinumab in the treatment of psoriasis: patient selection and perspectives
Yang EJ, Beck KM, Liao W
Psoriasis: Targets and Therapy 2018, 8:75-82
Published Date: 17 October 2018
The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA
Walsh JA, Jones H, Mallbris L, Callis Duffin K, Krueger GG, Clegg DO, Szumski A
Psoriasis: Targets and Therapy 2018, 8:65-74
Published Date: 8 October 2018
Evaluation of ADA activity as a potential marker of disease severity in psoriasis patients
Khan SA, Agrawal S, Baral N, Lamsal M
Psoriasis: Targets and Therapy 2018, 8:59-63
Published Date: 4 September 2018
Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
Beck KM, Sanchez IM, Yang EJ, Liao W
Psoriasis: Targets and Therapy 2018, 8:49-58
Published Date: 29 August 2018
The impact of genital psoriasis on quality of life: a systematic review
Yang EJ, Beck KM, Sanchez IM, Koo J, Liao W
Psoriasis: Targets and Therapy 2018, 8:41-47
Published Date: 28 August 2018
Abatacept for the treatment of adults with psoriatic arthritis: patient selection and perspectives
Noisette A, Hochberg MC
Psoriasis: Targets and Therapy 2018, 8:31-39
Published Date: 11 July 2018
Monitoring methotrexate-induced liver fibrosis in patients with psoriasis: utility of transient elastography
Cheng HS, Rademaker M
Psoriasis: Targets and Therapy 2018, 8:21-29
Published Date: 9 May 2018
Low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry
Gudbjornsson B, Geirsson AJ, Krogh NS
Psoriasis: Targets and Therapy 2018, 8:13-19
Published Date: 4 May 2018
Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis
Anzengruber F, Ghosh A, Maul JT, Drach M, Navarini AA
Psoriasis: Targets and Therapy 2018, 8:7-11
Published Date: 23 March 2018
Targeting IL-23 in psoriasis: current perspectives
Fotiadou C, Lazaridou E, Sotiriou E, Ioannides D
Psoriasis: Targets and Therapy 2018, 8:1-5
Published Date: 4 January 2018